We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

By LabMedica International staff writers
Posted on 10 Jan 2025

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company Innovaccer Inc. More...

(San Francisco, CA, USA) with the aim of improving patient outcomes and experience through novel digital and diagnostic solutions. The investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.

Innovaccer has developed a suite of software solutions designed to create a unified patient record to identify gaps in care and patients at risk, as well as appropriate interventions to improve patient outcomes. As part of the investment partnership, Danaher, along with Innovaccer and its network of healthcare systems, aims to accelerate the adoption of precision diagnostics both by clinicians and population health teams, facilitating value-based care.

"Patients are at the center of everything we do at Danaher. We believe our investment partnership with Innovaccer will empower patients and speed the transition to more personalized, value-based medicine by providing healthcare providers with the data and analytics needed to drive meaningful clinical insights, more quickly, and at the point of need," said Julie Sawyer Montgomery, Executive Vice President, Danaher Corporation.

"Danaher is committed to ethically using AI to develop and deliver better diagnostics to help doctors treat their patients with the right medicine in the right dose at the right time," said Murali Venkatesan, Head of Danaher Ventures, Americas & Europe and Vice President of Science, Technology and Innovation, Danaher Corporation. "We're excited to connect our innovation ecosystem with Innovaccer's to enable this healthcare transformation."

"At Innovaccer, we are on a mission to improve health outcomes through our data platform and AI capabilities," said Abhinav Shashank, cofounder and CEO of Innovaccer. "We believe that partnering with Danaher will accelerate our efforts to advance diagnostic and clinical AI solutions."

Related Links:
Danaher Corporation
Innovaccer Inc.


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The two new tests are used with the LightCycler 480 and LightCycler PRO instruments (Photo courtesy of Roche)

New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance

Cyclospora cayetanensis, a food- and waterborne intestinal parasite, can cause prolonged diarrhea, fatigue, and abdominal cramping, placing added strain on urgent care and emergency departments during outbreaks.... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.